Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

SNP-array lesions in core binding factor acute myeloid leukemia.

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Oncotarget. 2018 Jan 8;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

2.

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, Rey J, Bouvier Borg G, Gautherot E, Hamel JF, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Blaise D, Olive D.

Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.

3.

Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.

Couderc E, Morel F, Levillain P, Buffière-Morgado A, Camus M, Paquier C, Bodet C, Jégou JF, Pohin M, Favot L, Garcia M, Huguier V, Mcheik J, Lacombe C, Yssel H, Guillet G, Bernard FX, Lecron JC.

PLoS One. 2017 Jul 14;12(7):e0181486. doi: 10.1371/journal.pone.0181486. eCollection 2017.

4.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.

Chretien AS, Fauriat C, Orlanducci F, Galseran C, Rey J, Bouvier Borg G, Gautherot E, Granjeaud S, Hamel-Broza JF, Demerle C, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Gregori E, Luche H, Malissen M, Arnoulet C, Nunes JA, Vey N, Olive D.

Front Immunol. 2017 May 29;8:573. doi: 10.3389/fimmu.2017.00573. eCollection 2017.

5.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747.

6.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
7.

Comprehensive Proteomic Analysis of Human Erythropoiesis.

Gautier EF, Ducamp S, Leduc M, Salnot V, Guillonneau F, Dussiot M, Hale J, Giarratana MC, Raimbault A, Douay L, Lacombe C, Mohandas N, Verdier F, Zermati Y, Mayeux P.

Cell Rep. 2016 Aug 2;16(5):1470-1484. doi: 10.1016/j.celrep.2016.06.085. Epub 2016 Jul 21.

8.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

9.

ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration.

Auvynet C, Baudesson de Chanville C, Hermand P, Dorgham K, Piesse C, Pouchy C, Carlier L, Poupel L, Barthélémy S, Felouzis V, Lacombe C, Sagan S, Chemtob S, Quiniou C, Salomon B, Deterre P, Sennlaub F, Combadière C.

FASEB J. 2016 Jun;30(6):2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. Erratum in: FASEB J. 2017 Feb;31(2):852.

PMID:
26979087
10.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.

Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

11.

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Adam K, Lambert M, Lestang E, Champenois G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y, Mayeux P.

Biosci Rep. 2015 Oct 23;35(6). pii: e00274. doi: 10.1042/BSR20150217.

12.

Photos provide information on age, but not kinship, of Andean bear.

Van Horn RC, Zug B, Appleton RD, Velez-Liendo X, Paisley S, LaCombe C.

PeerJ. 2015 Jul 16;3:e1042. doi: 10.7717/peerj.1042. eCollection 2015.

13.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

14.

A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.

Bonaud A, Bender S, Touchard G, Lacombe C, Srour N, Delpy L, Oblet C, Druilhe A, Quellard N, Javaugue V, Cogné M, Bridoux F, Sirac C.

Blood. 2015 Aug 6;126(6):757-65. doi: 10.1182/blood-2015-03-630277. Epub 2015 Jun 25.

15.

Hepatocyte growth factor measurement in AL amyloidosis.

Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A.

Amyloid. 2015;22(2):112-6. doi: 10.3109/13506129.2015.1014548. Epub 2015 Jun 8.

PMID:
26053104
16.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J.

Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21.

17.

Erythropoiesis and transferrin receptors.

Moura IC, Hermine O, Lacombe C, Mayeux P.

Curr Opin Hematol. 2015 May;22(3):193-8. doi: 10.1097/MOH.0000000000000133. Review.

PMID:
25767952
18.

Recovery, as Experienced by Women with Borderline Personality Disorder.

Larivière N, Couture É, Blackburn C, Carbonneau M, Lacombe C, Schinck SA, David P, St-Cyr-Tribble D.

Psychiatr Q. 2015 Dec;86(4):555-68. doi: 10.1007/s11126-015-9350-x.

PMID:
25736797
19.

Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis.

Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M.

Biomark Med. 2015;9(3):187-97. doi: 10.2217/bmm.14.115.

PMID:
25731206
20.

Regulation of cell surface transferrin receptor-2 by iron-dependent cleavage and release of a soluble form.

Pagani A, Vieillevoye M, Nai A, Rausa M, Ladli M, Lacombe C, Mayeux P, Verdier F, Camaschella C, Silvestri L.

Haematologica. 2015 Apr;100(4):458-65. doi: 10.3324/haematol.2014.118521. Epub 2015 Jan 30.

21.

Rapid screening of classic galactosemia patients: a proof-of-concept study using high-throughput FTIR analysis of plasma.

Lacombe C, Untereiner V, Gobinet C, Zater M, Sockalingum GD, Garnotel R.

Analyst. 2015 Apr 7;140(7):2280-6. doi: 10.1039/c4an01942c.

PMID:
25622686
22.

Pachymodulin, a new functional formyl peptide receptor 2 peptidic ligand isolated from frog skin has Janus-like immunomodulatory capacities.

Lacombe C, Piesse C, Sagan S, Combadière C, Rosenstein Y, Auvynet C.

J Med Chem. 2015 Feb 12;58(3):1089-99. doi: 10.1021/jm501018q. Epub 2015 Feb 4.

PMID:
25587631
23.

Investigating the role of GXXXG motifs in helical folding and self-association of plasticins, Gly/Leu-rich antimicrobial peptides.

Carlier L, Joanne P, Khemtémourian L, Lacombe C, Nicolas P, El Amri C, Lequin O.

Biophys Chem. 2015 Jan;196:40-52. doi: 10.1016/j.bpc.2014.09.004. Epub 2014 Sep 28.

PMID:
25291467
24.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E.

Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27.

25.

Comment on "Evidence of a cascade and dissipation of solar-wind turbulence at the electron gyroscale".

Alexandrova O, Bale SD, Lacombe C.

Phys Rev Lett. 2013 Oct 4;111(14):149001. Epub 2013 Oct 2. No abstract available.

PMID:
24138275
26.

VBNC Legionella pneumophila cells are still able to produce virulence proteins.

Alleron L, Khemiri A, Koubar M, Lacombe C, Coquet L, Cosette P, Jouenne T, Frere J.

Water Res. 2013 Nov 1;47(17):6606-17. doi: 10.1016/j.watres.2013.08.032. Epub 2013 Sep 4.

PMID:
24064547
27.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

28.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S, Dreyfus F, Lacombe C, Béné MC, Kosmider O, Fontenay M, Bardet V.

Leukemia. 2013 Oct;27(10):1981-7. doi: 10.1038/leu.2013.178. Epub 2013 Jun 14.

PMID:
23765225
29.

Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.

Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, Ragot S, Aucouturier P, Touchard G, Bridoux F.

Am J Kidney Dis. 2013 Oct;62(4):679-90. doi: 10.1053/j.ajkd.2013.03.031. Epub 2013 Jun 4.

PMID:
23759297
30.

Age and aging in blood disorders: EHA theme of the year 2013-2014.

Chomienne C, McCann S, Green T, Hagenbeek A, Lacombe C, Guenova M, Roberts I, van der Beek I.

Haematologica. 2013 Jun;98(6):831-2. doi: 10.3324/haematol.2013.090415. No abstract available.

31.

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.

D'allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, Floquet C, Dubreuil P, Lacombe C, Fontenay M, Mayeux P, Kosmider O.

PLoS One. 2013 Apr 23;8(4):e60961. doi: 10.1371/journal.pone.0060961. Print 2013.

32.

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, Lamy T, Mayeux P, Lacombe C, Demur C, Tamburini J, Merlat A, Delepine R, Vey N, Dreyfus F, Béné MC, Ifrah N, Bouscary D; GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang).

Leukemia. 2013 Jul;27(7):1479-86. doi: 10.1038/leu.2013.17. Epub 2013 Jan 16.

PMID:
23321953
33.

Quality of life in hematology: European Hematology Association theme of the year...and years to come.

Chomienne C, Guenova M, Hagenbeek A, Lacombe C, McCann S, Salek S, Geissler J, van der Beek I.

Haematologica. 2013 Jan;98(1):2-3. doi: 10.3324/haematol.2012.080796. No abstract available.

34.

Al amyloidosis.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales.

Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Review.

35.

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

Ettou S, Audureau E, Humbrecht C, Benet B, Jammes H, Clozel T, Bardet V, Lacombe C, Dreyfus F, Mayeux P, Solary E, Fontenay M.

Leukemia. 2012 Oct;26(10):2297-9. doi: 10.1038/leu.2012.152. Epub 2012 Jun 5. No abstract available.

PMID:
22743624
36.

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.

Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, Boimard M, Touchard G, Goujon JM, Lacombe C, Lozeron P, Adams D, Lacroix C, Maisonobe T, Planté-Bordeneuve V, Vrana JA, Theis JD, Giorgetti S, Porcari R, Ricagno S, Bolognesi M, Stoppini M, Delpech M, Pepys MB, Hawkins PN, Bellotti V.

N Engl J Med. 2012 Jun 14;366(24):2276-83. doi: 10.1056/NEJMoa1201356.

37.

Evaluation of the zoonotic potential of Giardia duodenalis in fecal samples from dogs and cats in Ontario.

McDowall RM, Peregrine AS, Leonard EK, Lacombe C, Lake M, Rebelo AR, Cai HY.

Can Vet J. 2011 Dec;52(12):1329-33.

38.

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D.

Curr Oncol Rep. 2012 Apr;14(2):129-38. doi: 10.1007/s11912-012-0227-y. Review.

PMID:
22350330
39.

The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.

Hospital MA, Green AS, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Blood. 2012 Feb 16;119(7):1791-2. doi: 10.1182/blood-2011-11-393066. No abstract available.

40.

PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype.

Beauchemin D, Lacombe C, Van Themsche C.

Mol Cancer. 2011 Dec 14;10:148. doi: 10.1186/1476-4598-10-148.

41.

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène C, Sternberg A, Arlet JB, Floquet C, Gyan E, Kosmider O, Dreyfus F, Gabet AS, Courtois G, Vyas P, Ribeil JA, Zermati Y, Lacombe C, Mayeux P, Solary E, Garrido C, Hermine O, Fontenay M.

Blood. 2012 Feb 9;119(6):1532-42. doi: 10.1182/blood-2011-03-343475. Epub 2011 Dec 12.

42.

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6.

PMID:
22143671
43.

The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia.

Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Br J Haematol. 2012 Feb;156(4):547-50. doi: 10.1111/j.1365-2141.2011.08891.x. Epub 2011 Oct 14. No abstract available.

PMID:
21995271
44.

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V.

Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.

45.

Strategies to model AL amyloidosis in mice.

Sirac C, Bender S, Jaccard A, Bridoux F, Lacombe C, Touchard G, Cogné M.

Amyloid. 2011 Jun;18 Suppl 1:45-7. doi: 10.3109/13506129.2011.574354016. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:47.

PMID:
21838428
46.

Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?

Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G.

Clin J Am Soc Nephrol. 2011 Sep;6(9):2165-74. doi: 10.2215/CJN.06180710. Epub 2011 Jul 22.

47.

LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.

Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Cell Cycle. 2011 Jul 1;10(13):2115-20. Epub 2011 Jul 1. Review.

PMID:
21572254
48.

TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.

Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M; GOELAMS Investigators.

Haematologica. 2011 Jul;96(7):1059-63. doi: 10.3324/haematol.2011.040840. Epub 2011 Apr 20.

49.

Anti-Legionella activity of staphylococcal hemolytic peptides.

Marchand A, Verdon J, Lacombe C, Crapart S, Héchard Y, Berjeaud JM.

Peptides. 2011 May;32(5):845-51. doi: 10.1016/j.peptides.2011.01.025. Epub 2011 Feb 1.

PMID:
21291938
50.

Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease.

Boyer L, Chaar V, Pelle G, Maitre B, Chouaid C, Covali-Noroc A, Zerah F, Bucherer C, Lacombe C, Housset B, Dubois-Randé JL, Boczkowski J, Adnot S.

J Appl Physiol (1985). 2011 May;110(5):1196-203. doi: 10.1152/japplphysiol.01204.2010. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center